10/517240



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

371 of PCT/AU2003/000716

**Applicant** 

Eric Francis Morand et al.

International

Filing Date

June 6, 2003

TC/A.U.

Examiner

· :

Title :

Napththalene Derivatives Which Inhibit the Cytokine or Biological

Activity of Macrophage Migration Inhibitory Factor (MIF)

Docket No.

BDW002

Customer No.:

20786

Mail Stop PCT

December 7, 2004

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants cite the information on the attached Form PTO-1449, "List of Information Disclosed by Applicant," pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Applicants have enclosed a copy of each foreign patent document and other non-United States patent references cited therein.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Madeline I Johnston, Esq.

Reg. No. 36,174

King & Spalding LLP 191 Peachtree Street 45<sup>th</sup> Floor

Atlanta, GA 30303-1763 Tel.: (404) 572-4600

Fax: (404) 572-5145

3637655\_1.DOC

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT 17240

				(Use sever	ral sheets if necessary)		1075	1/6	<b>4</b> 0
ATTY. DOCKET NO.			SERIAL NO.		INTERNATIONAL FILING DATE				
BDW002					December 6, 2003				
APPLICANT					GROUP				
Eric Francis Morand et al.									
				U.S. PAT	ENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER DATE		NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,208,344	05/04/93	Kreft et a	1.				
	AB	5,084,575	01/28/92	Kreft et a	l				
	AC	4,910,208	03/20/90	Misra					
	AD	3,958,012	05/18/76	Fried et a	1.				
	AE	3,969,415	07/13/76	Galantay					
	AF	3,978,124	08/31/76	Fried et a	1.				
	AG	3,994,968	11/30/76	Alvarez				-	
	АН	3,998,966	12/21/76	Fried et a	1				
	AI	4,009,197	02/22/77	Fried et a	1.				
	AJ	3,904,682	09/09/75	Fried et a	1.				
	AK	3,935,273	01/27/76	Fried et a	1				
	AL	3,562,336	02/09/71	Nelson					
<del></del>	AM	5,268,458	12/07/93	Springer o	et al.			·· <del>· = ·· · · · · · · · · · · · · · · · </del>	
	AN	6,420,375	07/16/02	Aono et a					
	.	<u> </u>	F(	JKEIGN P	PATENT DOCUMENTS			TRANS	SLATION
		DOCUMENT NUMBER DATE COUNTRY NAME			YES NO.				
	AO	6809942	01/14/70	NL	Syntex Corp.				
	AP	2051012	04/20/72	DE	Syntex Corp.				
	AQ	2258349	06/07/93	DE	Sandoz				
EXAMINE	·				DATE CONSI	DERED		.,	<u> </u>
EXAMIN	ER: Ir	nitial if reference conside	ered, whether	or not citation	on is in conformance with MP	EP 609: Dra	w line through	citation if	not in
onforman	ce and	not considered. Include	copy of this i	form with ne	xt communication to applicant		J		

Sheet 2 of 4

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT 17240

(Use several sheets if necessary)

			`					
ATTY. DOCKET N	NO.	SERIAL NO.		INTERNATIONAL FILING DATE				
BDW002				December 6, 2003				
APPLICANT				GROUP				
Eric Francis M	orand et al.							
		F	OREIGN I	ATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTR	Y NAME	TRANS	LATION NO.		
AR	62-103074	05/13/87	JP	Hamari Yakuhin Kogyo KK				
AS	63-203631	08/23/88	JP	Nippon Kayaku Co. Ltd.		-		
АТ	279466 B1	08/24/88	EP	Warner-Lambert Co.				
AU	284359 B1	09/28/88	EP	Takeda Chemical Industries, Ltd.				
AV	286944 B1	10/19/88	EP	Enichem Synthesis S.p.A.		_		
AW	7 301813 B1	02/01/89	EP	American Home Products Corp.				
AX	372385 A2	06/13/90	EP	F. Hoffmann-La Roche AG				
AY	91/08744 A1	06/27/91	wo	Abbott Laboratories				
AZ	96/04267 A1	02/15/96	WO	Laboratorios Menarini S.A.				
ВА	97/31006 A1	08/28/97	wo	Glycomed Inc.				
ВВ	97/30992 A1	08/28/77	wo	Bristol-Myers Squibb Co.				
ВС	2329298	12/20/73	DE	Bottus				
BD	2442305	03/13/75	DT	Beecham Group Ltd.				
BE	7512107	01/30/76	NL	Syntex Corp.				
BF	52-133962	11/09/77	JР	Grelan Pharmaceut Co. Ltd.				
I								

Laboratorios Menarini, S.A. BJ 06/21/01 WO 01/44172 A1 Axys Pharaceuticals, Inc.

WO

ES

01/14/98 EP

01/14/99

12/01/00

01076063 03/22/89 JР Dainichiseika Color and Chemicals

10/31/84 123543 EP Merck Frosst Canada, Inc. **EXAMINER DATE CONSIDERED** 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Eli Lilly and Co.

Nycomed Amersham PLC

BG

BH

ΒI

BK

BL

0818453 B1

99/01768 A1

2150848 A1

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT 10/517240 ATTY. DOCKET NO. SERIAL NO. INTERNATIONAL FILING DATE BDW002 December 6, 2003 APPLICANT GROUP Eric Francis Morand et al. OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) BM Bosca et al., "A Photophysical and Photochemical Study of 6-Methoxy-2-Napthylacetic Acid, the Major Metabolite of the Phototoxic Nonsteroidal Aniinflammatory Drug Nabumetone", 2000, Photochemistry and Photobiology, Vol 71, No. 2, pgs. 173-177 BN Prabhakar et al., "Synthesis and Biological Activity of Novel Thiazolidinediones", 1998, Bioorganic and Medicinal Chemistry Letters, Vol. 8, No. 19, pgs. 2725-2730 BO Bosca et al., "New Photodegradation Pathways for Naproxen, a Phototoxic Nonsteroidal Antiinflammatory Drug", 1990, Preliminary Note in Journal of Photochemistry and Photobiology, Vol. 54, No. 1, pgs. 131-134 Hiyama et al., "A Facile, Practical Synthesis of 2-(6-Methoxy-2-Naphthyl)propenoic Acid", 1990, Bulletin of RP the Chemical Society of Japan, Vol. 63, No. 2, pgs. 640-642 BQ Harusawa et al., "A New Synthesis of Some Non-steroidal Anti-inflammatory Agents via Cyanophosphates, 1984, Synthetic Communications, Vol. 14, No. 14, pgs. 1365-1371 Ray et al., "High-Performance Liquid Chromatographic Determination of a New Anti-inflammatory Agent, BR Nabumetone, and its Major Metabolite in Plasma Using Fluorimetric Detection", 1984, Note in Journal of Chromatography, Vol. 336, No. 1, pgs. 234-238 BS Cavrini et al., "Synthesis of Derivatives of 2-Methoxynaphthalene as Potential Antiinflammatories", 1982, Farmaco, Edizione Scientifica, Vol. 37, No. 3, pgs. 171-178 Goudie et al., "4-(6-Methoxy-2-Naphthyl)Butan-2-One and Related Analogues, a Novel Structural Class of BT Antiinflammatory Compounds", 1978, Journal of Medicinal Chemistry, Vol 21, No. 12, pgs. 1260-1264 STN FILE CA Abstract No. 91:91390 and Tetrahedron Letters, 1978, Vol. 52, pgs. 5183-5186 BU BVSTN FILE CA Abstract No. 89:6137 and Kametani et al., 1987, Vol. 98, No. 2, pgs. 146-152 BW STN FILE CA Abstract No. 77:114208 and Journal of Heterocyclic Chemistry, 1972, Vol. 9, No. 4, pgs. 805-811 BXSTN FILE CA Abstract No. 71:81118 and Australian Journal of Chemistry, 1969, Vol. 22, No. 8, pgs. 1721-1730 BY STN FILE CA Abstract No. 67:79969 and Journal of Pharmaceutical Sciences, 1967, Vol. 56, No. 8, pgs. 993-997 **EXAMINER DATE CONSIDERED** EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 4

FORM PTO-1449, Adapted

# LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary) 10/5.17240

	·	-0/71/640				
ATTY. DOCKET NO.	SERIAL NO.	INTERNATIONAL FILING DATE				
BDW002		December 6, 2003				
APPLICANT		GROUP				
Eric Francis Morar	d et al.					
	OTHER REFERENCES (Incl.	uding Author, Title, Date, Pertinent Pages, Etc.)				
BZ	STN FILE CA Abstract No. 64:395 1364	0 and Australian Journal of Chemistry, 1965, Vol. 18, No. 9, pgs. 1351-				
CA	STN FILE CA Abstract No. 57:10708 and Journal of the American Chemical Society, 1962, Vol. 84, pgs. 85 862					
СВ	STN FILE CA Abstract No. 51:17182 and Chem. Listy, 1956, Vol. 50, pgs. 1610-1616					
EXAMINER		DATE CONSIDERED				
EYAMINED: Init	al if reference considered, whether or not city	ation is in conformance with MPEP 600: Draw line through citation if not in				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.